Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HuMax IL8 - Bristol-Myers Squibb/Genmab

Next Previous
X
Search
Drug Profile

HuMax IL8 - Bristol-Myers Squibb/Genmab

Alternative Names: anti-IL8 mAb - Bristol-Myers Squibb/Genmab; BMS-986253; HuMax-IL8; HuMax-Inflam; HuMax®-IL8; MDX 018

Latest Information Update: 20 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Medarex
  • Developer Bristol-Myers Squibb; Columbia University; Genmab; Icahn School of Medicine at Mount Sinai; Medarex; NYU Langone Health; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID 2019 infections; Liver cancer; Non-small cell lung cancer; Squamous cell cancer
  • Phase I/II Prostate cancer; Solid tumours
  • Discontinued Autoimmune disorders; Glioblastoma; Palmoplantar pustulosis

Most Recent Events

  • 06 Jun 2024 Bristol-Myers Squibb reinitiates enrollment in a phase I trial for Solid tumours (Combination therapy, Late stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT04572451)
  • 23 May 2024 Bristol-Myers Squibb suspends a phase I trial for Solid tumours (Combination therapy; Late stage disease, Metastatic disease, Inoperable/unresectable) in USA (IV) (NCT04572451)
  • 16 Nov 2023 Bristol-Myers Squibb in collaboration with Icahn School of Medicine at Mount Sinai completes a phase II trial in Liver cancer and Non-small Cell Lung Cancer (Combination therapy, Neoadjuvant therapy) in USA (PO) (NCT04123379)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top